|
|
Article: Maxygen and Biovitrum Sign Agreement to Manufacture Optimized Beta Interferon for Phase I and II Clinical Trials.
- Article from:
- PR Newswire
- Article date:
- June 8, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Maxygen, Inc. and Biovitrum AB today announced the signing of an agreement for the manufacture of Maxygen's improved interferon beta material for Phase I and Phase II clinical development.
"Biovitrum is a recognized leader in the production of protein pharmaceuticals," said Grant Yonehiro, Vice President Business Development of Maxygen. "The manufacturing of our improved interferon beta is an important part of our clinical development plan. We are focused on advancing this product candidate into clinical development for multiple sclerosis and potentially other indications and this deal takes us closer to realizing this goal."
"We are pleased to be ...